Cybersecurity Law amendment draft imposes heavier penalties. China proposes different data protection periods for three categories of drugs. Facial information collection requires obligations of informing individuals.
State Council restricts provision of evidence outside of mainland China for IP cases / CLP Reference: 5100/25.03.13 ; Promulgated: 2025-03-13 ; Effective: 2025-05-01
Total asset requirement is relaxed for Hong Kong and Macao insurance company investments / CLP Reference: 3910/25.02.26 ; Issued: 2025-02-26 ; Effective: 2025-03-01
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Jianwei (Jerry) Fang, Xiaoyu (Arthur) Jin and Haoyi Sun of Zhong Lun Law Firm discuss the reasons behind, and the implications of, Illumina’s inclusion in China’s Unreliable Entity List, as well as compliance recommendations for multinational corporations
China strengthens Anti-Foreign Sanctions Law in response to U.S. restrictions; Chinese firms move production facilities overseas amidst key economic changes; and China introduces regulations to protect interests in overseas IP disputes
China specifies penalties for a failure to implement sanction countering measures. Maximum fine for antitrust concentration is set at 10% of the previous year’s sales proceeds. State Council restricts provision of evidence outside of mainland China for IP cases.
A compliance audit is required when processing personal information of more than 10 million persons / CLP Reference: 5600/25.02.12 ; Promulgated: 2025-02-12; Effective: 2025-05-01
Multinationals must comply with new Chinese labeling requirements while the U.S. and EU have other specifications; A second Chinese court ruling affirms AI-generated images have copyright protection; and Supreme People’s Court cracks down on fraudulent behavior of prepayment service providers
